Articles related to SUDDEN CARDIAC DEATH (SDC)

According to reports, the second patient who passed away during the Phase 1 test of the cancer drug davoceticept by Alpine Immune Sciences experienced the same cardiovascular issue as the first patient.

Despite having anti-psychotic, anxiolytic, sedative, and hypnotic properties, quetiapine is linked to an increased risk of cardiovascular death and sudden cardiac death when used in conventional doses. For the first time, the current investigation demonstrated that quetiapine taken off-label and in modest doses raises the risk of major adverse cardiovascular events (MACE), stroke, and cardiovascular death.

The recommendations from the American Academy of Pediatrics (AAP) are an update to the group’s 2012 policy statement in an effort to better equip physicians with the necessary knowledge to accurately screen, evaluate, and manage the risk of both sudden cardiac arrest (SCA) and sudden cardiac death (SCD) in youth. Screening for all children, regardless of athletic status, should be completed at least every three years.

The action comes after observational evidence associating the HeartWare left ventricular assist device (LVAD) with increased neurological adverse events and mortality, as well as more than 100 complaints involving delay or failure to restart. First approved in November 2012, the LVAD has been implanted in approximately 2,000 US patients experiencing end-stage heart failure.

The FDA announced a trial hold after two participants with sickle cell disease (SCD) in the LentiGlobin gene therapy trials developed AML and MDS. According to bluebird bio, the manufacturer of LentiGlobin products, the company was unable to find any cancer cells in the patient’s bone marrow and has asked the FDA for permission to resume clinical trials.